Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L L Nielsen

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|December 14, 2006
Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylureaA Mari, L L Nielsen, N Nanayakkara, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|November 10, 2005
Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetesK Taylor, D Kim, L L Nielsen, et al.
Cancer Chemotherapy and Pharmacology|December 29, 2000
The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivoB Shi, B Yaremko, G Hajian, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 1, 1995
Mutations in the tumor suppressor gene p53 in human liver cancer induced by alpha-particlesM Andersson, M Jönsson, L L Nielsen, et al.
Human Gene Therapy|April 29, 1998
Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft modelsL L Nielsen, M Gurnani, J Syed, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|July 8, 1999
[Physiotherapy as manual therapy]T A Torstensen, L L Nielsen, R Jensen, et al.
Cancer Gene Therapy|August 7, 1998
A recombinant adenoviral vector expressing full-length human retinoblastoma susceptibility gene inhibits human tumor cell growthG W Demers, M P Harris, S F Wen, et al.
Cancer Gene Therapy|January 10, 2002
Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivoX Jin, R Bookstein, K Wills, et al.
Cancer Research|January 13, 2001
Derivation and initial characterization of a mouse mammary tumor cell line carrying the polyomavirus middle T antigen: utility in the development of novel cancer therapeuticsL L Nielsen, M Gurnani, B Shi, et al.
Diabetes, Obesity & Metabolism|November 26, 2009
Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care settingD I Brixner, C McAdam-Marx, X Ye, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|December 14, 2006
Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylureaA Mari, L L Nielsen, N Nanayakkara, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|November 10, 2005
Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetesK Taylor, D Kim, L L Nielsen, et al.
Cancer Chemotherapy and Pharmacology|December 29, 2000
The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivoB Shi, B Yaremko, G Hajian, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 1, 1995
Mutations in the tumor suppressor gene p53 in human liver cancer induced by alpha-particlesM Andersson, M Jönsson, L L Nielsen, et al.
Human Gene Therapy|April 29, 1998
Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft modelsL L Nielsen, M Gurnani, J Syed, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|July 8, 1999
[Physiotherapy as manual therapy]T A Torstensen, L L Nielsen, R Jensen, et al.
Cancer Gene Therapy|August 7, 1998
A recombinant adenoviral vector expressing full-length human retinoblastoma susceptibility gene inhibits human tumor cell growthG W Demers, M P Harris, S F Wen, et al.
Cancer Gene Therapy|January 10, 2002
Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivoX Jin, R Bookstein, K Wills, et al.
Cancer Research|January 13, 2001
Derivation and initial characterization of a mouse mammary tumor cell line carrying the polyomavirus middle T antigen: utility in the development of novel cancer therapeuticsL L Nielsen, M Gurnani, B Shi, et al.
Diabetes, Obesity & Metabolism|November 26, 2009
Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care settingD I Brixner, C McAdam-Marx, X Ye, et al.
Pageof 4